Precision oncology is entering a phase where the same molecular probe that finds a tumor can also destroy it — a concept called theranostics that is rapidly reshaping cancer treatment paradigms. For adults concerned about cancer risk and treatment options, understanding where this technology stands today and where it is heading matters considerably, as several agents are already approved and dozens more are advancing through late-stage trials.
Radiotheranostics pair a targeting ligand — often a peptide or small molecule — with a diagnostic radionuclide for imaging and a therapeutic radionuclide for cell killing, both directed at the same tumor-specific receptor. Currently approved agents include lutetium-177 PSMA-617 for metastatic castration-resistant prostate cancer and lutetium-177 DOTATATE for somatostatin receptor-positive neuroendocrine tumors. The review covers an expanding pipeline of novel radionuclides — including actinium-225, terbium isotopes, and lead-212 — that offer different particle energies and tissue penetration depths suited to varied tumor architectures. Emerging targets beyond PSMA and somatostatin receptors include fibroblast activation protein (FAP), carbonic anhydrase IX, and HER2, broadening potential indications to breast, renal, and other solid tumor types.
This review is particularly notable for its attention to operational and regulatory challenges in East and Southeast Asia, regions where radiopharmaceutical infrastructure is developing unevenly. From a broader research standpoint, theranostics occupy a genuinely transformative position: unlike systemic chemotherapy, these agents can deliver lethal radiation doses to individual metastatic lesions while largely sparing surrounding tissue, addressing a long-standing limitation in oncology. The main constraints remain isotope supply chain fragility, the need for specialized cyclotron or reactor facilities, and regulatory frameworks that lag behind clinical science. As a narrative review rather than a meta-analysis, it synthesizes the field authoritatively but introduces no new efficacy or safety data. For the health-conscious adult, the practical implication is that theranostic options are expanding meaningfully beyond prostate and neuroendocrine cancers within a realistic five-to-ten year horizon.